Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Revenue | $27.2M | $50.5M |
| Revenue growth | — | 85.9% |
| Gross profit | $20.0M | $38.0M |
| Gross margin | 73.8% | 75.3% |
| Operating income | -$24.1M | -$30.6M |
| Operating margin | -88.8% | -60.5% |
| Net income | -$24.3M | -$29.6M |
| Net margin | -89.3% | -58.7% |
| EPS (diluted) | -$6.11 | -$2.12 |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$25.5M | -$29.0M |
| Capital expenditures | $180K | $642K |
| Free cash flow | -$25.6M | -$29.6M |
| Fiscal year | FY2024 | FY2025 |
|---|---|---|
| Cash & equivalents | $40.1M | $85.8M |
| Total assets | $51.8M | $130M |
| Total liabilities | $26.2M | $31.3M |
| Long-term debt | $15.4M | $15.3M |
| Shareholders' equity | -$70.6M | $98.9M |
| Retained earnings | -$71.2M | -$101M |
| Shares (wtd avg diluted) | 4.07M | 14.2M |
Every figure is extracted from CARLSMED, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.